Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma

Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma

Several studies support the notion that the kinase inhibitor Imatinib mesylate exerts off-target effects on cells of the immune system. After our first report of continuous daily oral administration in subjects with relapsed/refractory neuroblastoma (NB, EudraCT: 2005–005778-63), here we update the...

Full description

Bibliographic Details
Main Authors: Fabio Morandi, Loredana Amoroso, Alessandra Dondero, Roberta Castriconi, Stefano Parodi, Roberto Luksch, Fiorina Casale, Aurora Castellano, Alberto Garaventa, Alessandro Moretta, Cristina Bottino, Mirco Ponzoni, Maria Valeria Corrias
Format: Article
Language:English
Published: Taylor & Francis Group 2018-09-01
Series:OncoImmunology
Subjects:
imatinib mesylate
neuroblastoma
pharmacokinetics
cytokines
nk cells
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1468953

Internet

http://dx.doi.org/10.1080/2162402X.2018.1468953

Similar Items